OSIVAX Revenue and Competitors

Lyon,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • OSIVAX's estimated annual revenue is currently $9.8M per year.(i)
  • OSIVAX's estimated revenue per employee is $168,362

Employee Data

  • OSIVAX has 58 Employees.(i)
  • OSIVAX grew their employee count by 5% last year.

OSIVAX's People

NameTitleEmail/Phone
1
Chief Business Development Officer and Chief Operating OfficerReveal Email/Phone
2
Head Clinical QAReveal Email/Phone
3
Head process developmentReveal Email/Phone
4
VP FinanceReveal Email/Phone
5
Director, Clinical DevelopmentReveal Email/Phone
6
Director Development and Co-funderReveal Email/Phone
7
Scientific Innovation ManagerReveal Email/Phone
8
Licensing, Alliances & Partnerships ManagerReveal Email/Phone
9
Project Manager - Responsable du Laboratoire QCReveal Email/Phone
10
Senior Clinical Project ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is OSIVAX?

Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies based on its proprietary technology oligoDOM® inducing powerful CD8 T-cell responses Osivax was created as a spin-off of Imaxio, a commercial-stage vaccine company, in order to accelerate the development of oligoDOM® technology platform oligoDOM® technology platform capitalizes on: - More than 12 years of R&D on a breakthrough approach to induce CD8 T-cell immunity - Clinical package developed by OSIVAX on a universal influenza vaccine candidate - Clinical and preclinical data generated by leading independent teams in Europe (Oxford University, DKFZ / Heidelberg University, Inserm / CNRS...) Osivax lead program is a game-changing universal influenza vaccine - Leveraging oligoDOM® technology, Osivax's team is developing a standalone recombinant vaccine to prevent moderate to severe cases of seasonal and pandemic influenza - This oligoDOM®-based universal influenza vaccine induces powerful CD8 T-cell immune responses against the highly conserved flu NucleoProtein (NP) and won't require annual updates as NP is a highly conserved antigen - The aim of this universal Influenza vaccine is to provide greater than 70% protection from morbidity and mortality caused by current and future A- and B-strain influenza viruses (1) - Osivax universal vaccine program is currently in phase I clinical trial, actively preparing a phase IIa Osivax relies on an international team with complementary life science experiences and a prestigious international Scientific Advisory Board with industry and academic expertises Osivax is based in Lyon (France) and Liège (Belgium), the two clusters of vaccine R&D in Europe. Osivax remains open to new collaborations, with partners looking for technologies to improve the immune response on otherwise poorly immunogenic antigens

keywords:N/A

N/A

Total Funding

58

Number of Employees

$9.8M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OSIVAX News

2022-04-19 - Are more powerful vaccines coming? Shots targeting T cells show promise.

A French biotechnology company called Osivax has been testing a T-cell vaccine for influenza, and they are now also developing one against...

2022-04-17 - Osivax Announces Publication of Phase 2a Trial Results for ...

Osivax is a biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to transform current...

2022-04-13 - Osivax Appoints Dr. Michael Watson, Former President of Moderna ...

Osivax is a biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to transform current...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.8M58-54%N/A
#2
$10.5M5823%N/A
#3
$7.7M595%N/A
#4
N/A6326%N/A
#5
$8.1M64N/AN/A